Mesoblast (ASX:MSB) has welcomed new research showing that its allogeneic cell therapy remestemcel-L delivers superior clinical outcomes compared with ruxolitinib for patients with steroid-refractory acute graft versus host disease. …
New analysis finds Mesoblast’s Remestemcel-L outperforms ruxolitinib in severe GvHD
December 14, 2025 Australian Biotech
Latest Video
Georgia Forrest
New Stories
-
The 'Dispatched' Podcast - Episode 1, Series 5
January 23, 2026 - - Podcast -
AusBiotech announces new advisory groups to support the life sciences sector
January 22, 2026 - - Latest News -
Specialised Therapeutics brings new hope to women with HER2-positive breast cancer in Thailand
January 22, 2026 - - Latest News -
New funding deal brings next-generation cystic fibrosis treatments closer for New Zealanders
January 22, 2026 - - Latest News -
For almost all of the last 40 years, Governments have aimed to make medicines less affordable, for everyone but them
January 22, 2026 - - Latest News -
argenx deepens Australian research footprint with Monash partnership
January 21, 2026 - - Latest News -
New data reinforce promise of cancer vaccine, with Australia playing a key role
January 21, 2026 - - Latest News